User login
CARLSBAD, CALIF. — Delayed thromboses have been observed after the cessation of double antiplatelet therapy in patients who have received an Enterprise stent for an intracranial aneurysm.
Seven of 213 patients in the Interstate Collaboration of the Enterprise Stent Coiling (ICES) Multicenter Registry experienced a thrombotic event 2-24 weeks after placement of the stent and stopping aspirin and clopidogrel, Dr. J. Mocco reported at the annual meeting of the Society of Neurointerventional Surgery. Another two patients experienced acute cases of stent thrombosis.
Ten U.S. sites participate in the registry to rapidly provide large-volume, real-world results regarding experience in using the Enterprise Vascular Reconstruction Device and Delivery System (J. Neurosurg. 2009;110:35-9) for the treatment of intracranial aneurysms. The stent system is designed to assist in the embolic coiling of wide-neck aneurysms.
In the seven cases, the patients either did not comply with the drug regimen or stopped taking the antiplatelets on the order of the physician.
The data suggest that early cessation of double antiplatelet therapy is not ideal; but it is currently unclear what the optimum time course should be, said Dr. Mocco, an endovascular neurosurgeon at the University of Florida, Gainesville.
Use of the Enterprise stent was linked with 90% or greater occlusion in 88% of aneurysms. Permanent morbidity (all minor) occurred in 1.4% of patients.
None of the thrombotic events were associated with coil prolapse or parent vessel tortuosity, said Dr. Mocco. Three events had no angiographic corollary, and two were diagnosed based on symptoms.
Dr. Mocco gave his presentation at a session sponsored by Codman Neurovascular, maker of the Enterprise stent. He said that he received no direct financial support from Codman, and the data were generated independent of commercial influence, although the University of Florida receives an educational grant and consulting fees from Codman.
CARLSBAD, CALIF. — Delayed thromboses have been observed after the cessation of double antiplatelet therapy in patients who have received an Enterprise stent for an intracranial aneurysm.
Seven of 213 patients in the Interstate Collaboration of the Enterprise Stent Coiling (ICES) Multicenter Registry experienced a thrombotic event 2-24 weeks after placement of the stent and stopping aspirin and clopidogrel, Dr. J. Mocco reported at the annual meeting of the Society of Neurointerventional Surgery. Another two patients experienced acute cases of stent thrombosis.
Ten U.S. sites participate in the registry to rapidly provide large-volume, real-world results regarding experience in using the Enterprise Vascular Reconstruction Device and Delivery System (J. Neurosurg. 2009;110:35-9) for the treatment of intracranial aneurysms. The stent system is designed to assist in the embolic coiling of wide-neck aneurysms.
In the seven cases, the patients either did not comply with the drug regimen or stopped taking the antiplatelets on the order of the physician.
The data suggest that early cessation of double antiplatelet therapy is not ideal; but it is currently unclear what the optimum time course should be, said Dr. Mocco, an endovascular neurosurgeon at the University of Florida, Gainesville.
Use of the Enterprise stent was linked with 90% or greater occlusion in 88% of aneurysms. Permanent morbidity (all minor) occurred in 1.4% of patients.
None of the thrombotic events were associated with coil prolapse or parent vessel tortuosity, said Dr. Mocco. Three events had no angiographic corollary, and two were diagnosed based on symptoms.
Dr. Mocco gave his presentation at a session sponsored by Codman Neurovascular, maker of the Enterprise stent. He said that he received no direct financial support from Codman, and the data were generated independent of commercial influence, although the University of Florida receives an educational grant and consulting fees from Codman.
CARLSBAD, CALIF. — Delayed thromboses have been observed after the cessation of double antiplatelet therapy in patients who have received an Enterprise stent for an intracranial aneurysm.
Seven of 213 patients in the Interstate Collaboration of the Enterprise Stent Coiling (ICES) Multicenter Registry experienced a thrombotic event 2-24 weeks after placement of the stent and stopping aspirin and clopidogrel, Dr. J. Mocco reported at the annual meeting of the Society of Neurointerventional Surgery. Another two patients experienced acute cases of stent thrombosis.
Ten U.S. sites participate in the registry to rapidly provide large-volume, real-world results regarding experience in using the Enterprise Vascular Reconstruction Device and Delivery System (J. Neurosurg. 2009;110:35-9) for the treatment of intracranial aneurysms. The stent system is designed to assist in the embolic coiling of wide-neck aneurysms.
In the seven cases, the patients either did not comply with the drug regimen or stopped taking the antiplatelets on the order of the physician.
The data suggest that early cessation of double antiplatelet therapy is not ideal; but it is currently unclear what the optimum time course should be, said Dr. Mocco, an endovascular neurosurgeon at the University of Florida, Gainesville.
Use of the Enterprise stent was linked with 90% or greater occlusion in 88% of aneurysms. Permanent morbidity (all minor) occurred in 1.4% of patients.
None of the thrombotic events were associated with coil prolapse or parent vessel tortuosity, said Dr. Mocco. Three events had no angiographic corollary, and two were diagnosed based on symptoms.
Dr. Mocco gave his presentation at a session sponsored by Codman Neurovascular, maker of the Enterprise stent. He said that he received no direct financial support from Codman, and the data were generated independent of commercial influence, although the University of Florida receives an educational grant and consulting fees from Codman.